Recent Updates
Recently added Catalysts
CBLL Positive Sentiment

Ceribell to Present at the 42nd Annual J.P. Morgan Healthcare Conference Ceribell, Inc.®, the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao, Ph.D., CEO and Co-founder, will...

Key Takeaway: Ceribell, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. CEO Jane Chao will discuss the company's innovative AI-powered EEG system, which is FDA-approved for diagnosing electrographic status epilepticus. The technology aims to enhance the efficiency and accessibility of EEG diagnostics in acute care settings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell's AI-powered EEG system is the first of its kind.
  • The company is presenting at a prestigious healthcare conference.
  • Ceribell's technology has FDA approval and CMS payment support.
  • The system improves efficiency in seizure management.

Full Press Release Details

SUNNYVALE, Calif. , Jan. 4, 2024 /PRNewswire/ -- Ceribell, Inc. ® , the developer of the first AI-powered point-of-care EEG system, announced today that Jane Chao , Ph.D., CEO and Co-founder, will present at the upcoming 42 nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024 , at 8:00 a.m. Pacific Standard Time .
Event: 42 nd Annual J.P. Morgan Healthcare Conference Date: Monday, January 8, 2024 Time: 8:00 a.m. PST
About Ceribell The Ceribell ClarityPro™ AI algorithm is revolutionizing seizure management in acute care with the first and only FDA-indicated software for the diagnosis of electrographic status epilepticus with U.S. Centers for Medicare and Medicaid Services approved New Technology Add-on Payment (NTAP). Ceribell's mission is to make EEG diagnostics widely available, more efficient, and more cost-effective, to improve the detection and treatment of neurological conditions. The Ceribell system provides rapid access to accurate diagnostic information and continuous monitoring at the bedside 24/7, enabling precise patient care and hospital-wide efficiencies. The Ceribell system first received FDA 510(k) clearance in 2017 and is commercially available in the United States . For more information visit www.ceribell.com .
Investor Contacts: Brian Johnston or Laine Morgan Gilmartin Group LLC [email protected] [email protected]

Frequently Asked Questions

What is the date of Ceribell's presentation?

Ceribell's presentation is scheduled for January 8, 2024.

Who will present at the J.P. Morgan Conference?

Jane Chao, Ph.D., CEO and Co-founder of Ceribell, will present.

What technology will Ceribell discuss?

Ceribell will discuss its AI-powered point-of-care EEG system.

What is the significance of Ceribell's EEG system?

It is the first FDA-indicated software for diagnosing electrographic status epilepticus.

Last updated: Jan 4, 2024